METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets genetic fatty liver in Mid-Stage trial
Disease control Recruiting nowThis Phase 2a trial is testing a new drug called ALN-PNP, alone or with a weight-loss drug (tirzepatide), in 204 adults with a specific genetic form of fatty liver disease (MASLD). The goal is to see if lowering a certain liver protein can reduce liver fat. Participants must have…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New RNA drug targets fatty liver in people with specific gene
Disease control Recruiting nowThis study tests an experimental drug called ALN-PNP in healthy adults and people with a liver condition called MASLD who have a specific gene variant. The main goal is to check safety and how the body handles the drug. It is a first-in-human trial, so the drug is not yet approve…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug aims to shrink fatty liver in early trial
Disease control Recruiting nowThis early-stage study tests a drug called miricorilant in 8 people with MASH, a type of fatty liver disease linked to metabolism. The goal is to see if the drug can lower the amount of new fat the liver makes and reduce overall liver fat after 6 weeks. Participants must have cer…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Vitamin B3 shows promise in fighting fatty liver disease
Disease control Recruiting nowThis study tests whether taking a low dose of niacin (vitamin B3) after meals can help reduce fat stored in the liver for people with metabolic fatty liver disease (MASLD). Researchers will compare niacin to a placebo in 36 adults aged 50 to 80. The goal is to see if niacin can r…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: NA • Sponsor: Université de Sherbrooke • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug miricorilant tested for fatty liver disease safety
Knowledge-focused Recruiting nowThis early-stage study is testing a single dose of the drug miricorilant in 15 adults with MASH (a type of fatty liver disease) or MASH with cirrhosis. The main goal is to see how the body processes the drug and whether it is safe. This is not a test of whether the drug works, bu…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC